Full Text View
Tabular View
No Study Results Posted
Related Studies
Treatment Efficacy of OMT for Carpal Tunnel Syndrome
This study is currently recruiting participants.
Study NCT00394043   Information provided by University of North Texas Health Science Center
First Received: October 27, 2006   No Changes Posted

October 27, 2006
October 27, 2006
October 2006
 
  • Changes in the Median motor and sensory distal latencies.
  • Improvement in the patients'self-reported symptoms and functionality scores.
Same as current
No Changes Posted
  • Strength measured with one grip and three pinch strength tests.
  • Changes in sensation as measured by Current Perceptual Threshold.
  • Changes in the transverse and anterior/posterior interior diameters and cross-sectional areas of the carpal tunnel.
  • Carpal tunnel edema.
Same as current
 
Treatment Efficacy of OMT for Carpal Tunnel Syndrome
Treatment Efficacy of OMT for Carpal Tunnel Syndrome

This study will investigate whether an eight-week regimen of osteopathic manipulative treatment will have immediate and lasting positive effects on the symptoms, functional limitation and physiologic impairment associated with Carpal Tunnel Syndrome.

The incidence of Carpal Tunnel Syndrome (CTS) in adults in the U.S. ranges from 15-20% depending on the study, and costs over one billion dollars annually in medical care. Surgery for CTS accounts for much of these costs with up to one third of these patients experiencing re-occurrence of symptoms post-operatively.

The overall goal for this proposed exploratory clinical trial is to evaluate the efficacy of a conservative, manual medicine treatment as an adjunctive therapy to standard care for CTS. This pilot study utilizes a prospective, randomized, placebo-controlled clinical trial methodology to examine whether an eight week treatment regimen of osteopathic manipulative treatment (OMT) when used adjunctively to standard therapy will have immediate and lasting positive effects on the symptoms, functional limitations, and physiologic impairment associated with CTS.

Male and female subjects between the ages of 20 and 65 who meet electro-physiologic and symptom/functional inclusion criteria will be randomly assigned to one of three study groups, all of which will continue standard medical care with their treating physician/provider; (i) OMT plus standard medical care; (ii) placebo (sub-therapeutic ultrasound) plus standard medical care; and (iii) standard medical care only (no-treat).

Outcome measures are: 1. Median and Ulnar motor and sensory nerve conduction amplitudes and distal latencies, 2. Symptoms and Functional status, 3. Strength, 4. Sensation, 5. Interior dimensions of the carpal tunnel, and 6. Quantification (signal intensity by MRI) of water (edema) in the Median nerve and carpal tunnel. Placebo potency and blinding success will be evaluated. A preliminary investigation demonstrates our ability to recruit subjects and measure these outcomes. Power analysis based upon a decrease in the mean median motor nerve distal latency of 30% identified a minimum number of 42 subjects per treatment group.

It is expected that a significantly greater number of subjects in the OMT adjunctive treatment group will achieve the effective change in nerve latency compared to the other two treatment groups. It is also expected that the OMT adjunctive treatment group will have greater improvement of all physiological and clinical outcome measures than the other two groups. It is anticipated that the findings of this preliminary clinical trial will provide a basis for the development of a multi-center clinical trial to compare the outcomes of conservative non-surgical manual medicine treatments with the outcomes of surgical treatments of CTS.

Phase II
Interventional
Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Carpal Tunnel Syndrome
  • Procedure: Osteopathic Manipulative Treatment
  • Procedure: Placebo Sub-Therapeutic Ultrasound
  • Procedure: Standard Medical Care
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Recruiting
138
October 2009
 

Inclusion Criteria:

  • Men and women with a self-reported medical diagnosis of unilateral or bilateral CTS, between the ages of 21 and 65 and all races and ethnic groups.
  • Median motor nerve distal latency greater than 4.2 ms
  • A difference between ipsilateral Median and Ulnar motor nerve distal latency greater than 1.5 ms.
  • Median nerve sensory nerve distal latency greater than 2.2 ms
  • A difference between Median and Ulnar sensory nerve peak distal latency greater than 0.2 ms

Exclusion Criteria:

  • severe CTS that has progressed to muscle atrophy
  • pregnancy
  • previous wrist surgery on the wrist to be studied
  • systemic disease or condition including but not limited to diabetes mellitus, thyroid disorders, rheumatoid disorders, Paget's bone disease, gout, myxedema, multiple myeloma, acromegaly, hepatic disease, dialysis patients, or other diseases or conditions in which peripheral neuropathies are common.
  • secondary cause of CTS such as a ganglion cyst, mass, or an accessory muscle shown by an MRI exam of the wrist.
Both
21 Years to 65 Years
No
Contact: Scott T Stoll, D.O., Ph.D. 817-735-2114 ORCresearch@hsc.unt.edu
United States
 
NCT00394043
 
1R21 AT002303-01A2
University of North Texas Health Science Center
Osteopathic Research Center
Principal Investigator: Scott T Stoll, D.O., Ph.D. Osteopathic Research Center University of North Texas Health Science Center
University of North Texas Health Science Center
October 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP